<DOC>
	<DOCNO>NCT01008475</DOCNO>
	<brief_summary>The purpose study assess safety clinical activity experimental drug EMD 525797 ( study drug ) , monoclonal antibody target alfa integrins , combination irinotecan cetuximab K-ras wildtype metastatic colorectal cancer patient .</brief_summary>
	<brief_title>EMD 525797 Combination With Cetuximab Irinotecan K-ras Wild Type Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Subjects histologically confirm kras wildtype ( WT ) colorectal carcinoma ( CRC ) document distant metastasis Prior oxaliplatin/fluoropyrimidinecontaining regimen firstline treatment metastatic disease Failed oxaliplatin regimen metastatic colorectal carcinoma ( mCRC ) . Failure define either progressive disease ( PD ) ( clinical radiologic ) within 6 month last dose agent oxaliplatinbased regimen intolerance oxaliplatin regimen . Intolerance oxaliplatin regimen define discontinuation due following : severe allergic reaction , persistent severe neurotoxicity , delayed recovery toxicity prevent retreatment At least 1 radiographically document measurable lesion previously non irradiated area accord Response Evaluation Criteria In Solid Tumors ( RECIST , Version 1.0 ) , i.e. , lesion must adequately measurable least 1 dimension ( long diameter record ) great equal ( &gt; = ) 2 centimeter ( cm ) conventional technique &gt; =1 cm spiral compute tomography ( CT ) scan Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 , Karnofsky performance status ( KPS ) &gt; = 80 percent ( % ) Absolute Neutrophil Count ( ANC ) &gt; =1.5 x 10^9/Liter Platelets &gt; =100 x 10^9/Liter Hemoglobin &gt; =9 gram per deciliter ( g/dL ) ( without transfusion ) Bilirubin le equal ( &lt; = ) 1.5 x upper limit normal ( ULN ) Aspartate transaminase ( AST ) &lt; =5 x ULN alanine transaminase ( ALT ) &lt; =5 x ULN Serum creatinine &lt; =1.25 x ULN and/or creatinine clearance &gt; =50 milliliter per minute ( mL/min ) International Nationalized Ratio ( INR ) , partial thromboplastin time ( PTT ) within normal limit Sodium potassium within normal limit &lt; =10 % ( supplementation permit ) Previous treatment inhibitor Epidermal Growth Factor Receptor ( EGFR ) Known brain metastasis and/or leptomeningeal disease Radiotherapy ( except localize radiotherapy pain relief ) , major surgery , investigational drug 30 day start trial treatment entry ; plan major surgery trial Concurrent chronic systemic immune hormone therapy indicate trial protocol ( except physiologic replacement ; steroid 10 mg prednisone equivalent topical inhale steroid allow ) Clinically relevant coronary artery disease ( New York Heart Association [ NYHA ] functional angina classification III/IV ) , congestive heart failure ( NYHA III/IV ) , clinically relevant cardiomyopathy , history myocardial infarction last 12 month , high risk uncontrolled arrhythmia Uncontrolled hypertension define systolic blood pressure &gt; =160 millimeter mercury ( mmHg ) and/or diastolic blood pressure &gt; =100 mmHg rest condition History coagulation disorder associate bleed recurrent thrombotic event History recent peptic ulcer disease ( endoscopically proven gastric , duodenal esophageal ulcer ) within 6 month trial treatment start Chronic inflammatory bowel disease , acute/chronic ileus Active infection ( require i.v . antibiotic ) , include active tuberculosis , active chronic Hepatitis B C , ongoing HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>EMD 525797</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>metastatic colorectal cancer</keyword>
</DOC>